167 related articles for article (PubMed ID: 8172680)
21. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
[TBL] [Abstract][Full Text] [Related]
22. Intracellular transport of molecules engaged in the presentation of exogenous antigens.
Nordeng TW; Gorvel JP; Bakke O
Curr Top Microbiol Immunol; 1998; 232():179-215. PubMed ID: 9557399
[No Abstract] [Full Text] [Related]
23. MHC class II molecules traffic into lipid rafts during intracellular transport.
Poloso NJ; Muntasell A; Roche PA
J Immunol; 2004 Oct; 173(7):4539-46. PubMed ID: 15383586
[TBL] [Abstract][Full Text] [Related]
24. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
25. Lysosomal cysteine and aspartic proteases are heterogeneously expressed and act redundantly to initiate human invariant chain degradation.
Costantino CM; Hang HC; Kent SC; Hafler DA; Ploegh HL
J Immunol; 2008 Mar; 180(5):2876-85. PubMed ID: 18292509
[TBL] [Abstract][Full Text] [Related]
26. Transport and intracellular distribution of MHC class II molecules and associated invariant chain in normal and antigen-processing mutant cell lines.
Riberdy JM; Avva RR; Geuze HJ; Cresswell P
J Cell Biol; 1994 Jun; 125(6):1225-37. PubMed ID: 8207055
[TBL] [Abstract][Full Text] [Related]
27. Presentation of antigens by MHC class II molecules: getting the most out of them.
Villadangos JA
Mol Immunol; 2001 Sep; 38(5):329-46. PubMed ID: 11684289
[TBL] [Abstract][Full Text] [Related]
28. Developing and shedding inhibitions: how MHC class II molecules reach maturity.
Busch R; Mellins ED
Curr Opin Immunol; 1996 Feb; 8(1):51-8. PubMed ID: 8729446
[TBL] [Abstract][Full Text] [Related]
29. Intracellular transport of MHC class II and associated invariant chain in antigen presenting cells from AP-3-deficient mocha mice.
Sevilla LM; Richter SS; Miller J
Cell Immunol; 2001 Jun; 210(2):143-53. PubMed ID: 11520080
[TBL] [Abstract][Full Text] [Related]
30. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection.
Martin WD; Hicks GG; Mendiratta SK; Leva HI; Ruley HE; Van Kaer L
Cell; 1996 Feb; 84(4):543-50. PubMed ID: 8598041
[TBL] [Abstract][Full Text] [Related]
31. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
32. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
33. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
Dissanayake SK; Tuera N; Ostrand-Rosenberg S
J Immunol; 2005 Feb; 174(4):1811-9. PubMed ID: 15699107
[TBL] [Abstract][Full Text] [Related]
34. The role of the invariant chain in mucosal immunity.
Barrera CA; Almanza RJ; Ogra PL; Reyes VE
Int Arch Allergy Immunol; 1998 Oct; 117(2):85-93. PubMed ID: 9784651
[TBL] [Abstract][Full Text] [Related]
35. Coalescence of B cell receptor and invariant chain MHC II in a raft-like membrane domain.
Hauser JT; Lindner R
J Leukoc Biol; 2014 Nov; 96(5):843-55. PubMed ID: 25024398
[TBL] [Abstract][Full Text] [Related]
36. Intracellular organelles involved in antigen processing and the binding of peptides to class II MHC molecules.
Harding CV
Semin Immunol; 1995 Dec; 7(6):355-60. PubMed ID: 8775461
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylation of the invariant chain by protein kinase C regulates MHC class II trafficking to antigen-processing compartments.
Anderson HA; Bergstralh DT; Kawamura T; Blauvelt A; Roche PA
J Immunol; 1999 Nov; 163(10):5435-43. PubMed ID: 10553069
[TBL] [Abstract][Full Text] [Related]
38. Deletion of a C-terminal sequence of the class II-associated invariant chain abrogates invariant chains oligomer formation and class II antigen presentation.
Bertolino P; Staschewski M; Trescol-Biémont MC; Freisewinkel IM; Schenck K; Chrétien I; Forquet F; Gerlier D; Rabourdin-Combe C; Koch N
J Immunol; 1995 Jun; 154(11):5620-9. PubMed ID: 7751615
[TBL] [Abstract][Full Text] [Related]
39. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
Gregers TF; Fleckenstein B; Vartdal F; Roepstorff P; Bakke O; Sandlie I
Int Immunol; 2003 Nov; 15(11):1291-9. PubMed ID: 14565927
[TBL] [Abstract][Full Text] [Related]
40. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion.
Neumann J; Eis-Hübinger AM; Koch N
J Immunol; 2003 Sep; 171(6):3075-83. PubMed ID: 12960333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
